局部晚期NSCLC放疗联合分子靶向治疗的研究进展

摘要

对于不能手术切除的局部晚期NSCLC,单纯放疗或放化疗是主要治疗手段,但总体疗效并不理想.近些年来,分子靶向治疗使局部晚期肺癌的治疗有了突破性进展,其中EGFR抑制剂和VEGF抑制剂的应用较为广泛.目前,对于局部晚期NSCLC越来越多的研究侧重于放疗联合分子靶向治疗方面,现有的Ⅰ—Ⅲ期临床研究显示,放疗联合分子靶向这种新治疗模式能否与同步放化疗、序贯放化疗和单纯放疗这三种目前现有的治疗模式相比,有待进一步探究.本文针对局部晚期的NSCLC放疗联合靶向治疗进行系统性的分析.%Radiotherapy alone and chemoradiotherapy are main approaches for treating unresectable locally advanced non-small cell lung cancer (NSCLC). However, the overall efficacy of these treatment approaches is far from satisfactory. Recently, targeted molecular therapy has become a milestone in the treatment of locally advanced lung cancer. Particularly, inhibitors of epidermal endothelial growth factor and vascular endothelial growth factor have been widely used. Right now, more and more studies focus on radiotherapy combined with targeted molecular therapy for treating locally advanced NSCLC. According to the reported phaseⅠ-Ⅲclinical trials, whether radiotherapy combined with targeted molecular therapy has better efficacy than concurrent chemoradiotherapy, sequential chemoradiotherapy, or radiotherapy alone still needs further studies. This paper provides a systematic analysis of radiotherapy combined with targeted molecular therapy for locally advanced NSCLC.